Designing Benefits and Payment Models for Innovative High-Investment Medications Partnership Forum
New health care technologies and innovations are rapidly bringing the promise of life changing treatment for specific diseases. It is imperative that financial models for innovative, high-investment medications be developed to maintain patient access. The AMCP Partnership Forum, Designing Benefits and Payment Models for Innovative High-Investment Medications, took place on July 24-25, 2018 in Baltimore, MD.
The AMCP Partnership Forum, Designing Benefits and Payment Models for Innovative, High-Investment Medications, gathered more than 30 experts representing health plans, integrated delivery systems, pharmacy benefit managers, employers, national professional associations, the federal government, and biopharmaceutical companies. New payment models are needed to address the emerging high-investment medications, participants agreed.
The event was held in partnership with Abbvie, Alnylam Pharmaceuticals, Amgen, AstraZeneca, Celgene, Gilead, the National Pharmaceutical Council, the Pharmaceutical Research and Manufacturers of America, Takeda, and Xcenda/AmerisourceBergen.